{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T19:49:45Z","timestamp":1769111385595,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,3,12]],"date-time":"2018-03-12T00:00:00Z","timestamp":1520812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s10741-018-9689-9","type":"journal-article","created":{"date-parts":[[2018,3,11]],"date-time":"2018-03-11T22:30:08Z","timestamp":1520807408000},"page":"547-553","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Is there a blood pressure lowering effect of MRAs in heart failure? An overview and meta-analysis"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1009-9772","authenticated-orcid":false,"given":"George","family":"Bazoukis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Costas","family":"Thomopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Tse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Costas","family":"Tsioufis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,12]]},"reference":[{"key":"9689_CR1","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ et al (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J 37:2129\u20132200","journal-title":"Eur Heart J"},{"key":"9689_CR2","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1097\/HJH.0b013e3280d9434e","volume":"25","author":"F Zannad","year":"2007","unstructured":"Zannad F (2007) Aldosterone antagonist therapy in resistant hypertension. J Hypertens 25:747\u2013750","journal-title":"J Hypertens"},{"key":"9689_CR3","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","volume":"34","author":"G Mancia","year":"2013","unstructured":"Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M et al (2013) 2013 ESH\/ESC guidelines for the Management of Arterial Hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34:2159\u20132219","journal-title":"Eur Heart J"},{"key":"9689_CR4","doi-asserted-by":"crossref","unstructured":"Bazoukis G, Thomopoulos C, Tsioufis C (2017) Effect of mineralocorticoid antagonists on blood pressure lowering: overview andmeta-analysis of randomized controlled trials in hypertension journal of hypertension:35","DOI":"10.1097\/HJH.0000000000001671"},{"key":"9689_CR5","doi-asserted-by":"crossref","unstructured":"Rossignol P, Claggett B, Liu J, Vardeny O, Pitt B, Zannad F, et al. (2017) Spironolactone and resistant hypertension in heart failure with preserved ejection fraction. American journal of hypertension.","DOI":"10.1093\/ajh\/hpx210"},{"key":"9689_CR6","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ 339:b2535","journal-title":"BMJ"},{"key":"9689_CR7","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/jama.2013.905","volume":"309","author":"F Edelmann","year":"2013","unstructured":"Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W et al (2013) Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: The Aldo-DHF randomized controlled trial. JAMA 309:781\u2013791","journal-title":"JAMA"},{"key":"9689_CR8","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1161\/01.CIR.0000138680.89536.A9","volume":"110","author":"PM Mottram","year":"2004","unstructured":"Mottram PM, Haluska B, Leano R, Cowley D, Stowasser M, Marwick TH (2004) Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 110:558\u2013565","journal-title":"Circulation"},{"key":"9689_CR9","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.cardfail.2011.04.007","volume":"17","author":"A Deswal","year":"2011","unstructured":"Deswal A, Richardson P, Bozkurt B, Mann DL (2011) Results of the randomized aldosterone antagonism in heart failure with preserved ejection fraction trial (RAAM-PEF). J Card Fail 17:634\u2013642","journal-title":"J Card Fail"},{"key":"9689_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H et al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:11\u201321","journal-title":"N Engl J Med"},{"key":"9689_CR11","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1016\/j.jacc.2009.08.021","volume":"54","author":"GJ Mak","year":"2009","unstructured":"Mak GJ, Ledwidge MT, Watson CJ, Phelan DM, Dawkins IR, Murphy NF et al (2009) Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J Am Coll Cardiol 54:1674\u20131682","journal-title":"J Am Coll Cardiol"},{"key":"9689_CR12","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309\u20131321","journal-title":"N Engl J Med"},{"key":"9689_CR13","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B et al (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370:1383\u20131392","journal-title":"N Engl J Med"},{"key":"9689_CR14","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1161\/01.CIR.0000030935.89559.04","volume":"106","author":"UP Jorde","year":"2002","unstructured":"Jorde UP, Vittorio T, Katz SD, Colombo PC, Latif F, Le Jemtel TH (2002) Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure. Circulation 106:1055\u20131057","journal-title":"Circulation"},{"key":"9689_CR15","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1097\/HJH.0000000000000972","volume":"34","author":"C Thomopoulos","year":"2016","unstructured":"Thomopoulos C, Parati G, Zanchetti A (2016) Effects of blood pressure lowering treatment in hypertension: 8. Outcome reductions vs discontinuations because of adverse drug events - meta-analyses of randomized trials. J Hypertens 34:1451\u20131463","journal-title":"J Hypertens"},{"key":"9689_CR16","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s12872-016-0425-x","volume":"16","author":"NM Berbenetz","year":"2016","unstructured":"Berbenetz NM, Mrkobrada M (2016) Mineralocorticoid receptor antagonists for heart failure: Systematic review and meta-analysis. BMC Cardiovasc Disord 16:246","journal-title":"BMC Cardiovasc Disord"},{"key":"9689_CR17","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"B Pitt","year":"2013","unstructured":"Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H et al (2013) Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: A randomized, double-blind trial. Eur Heart J 34:2453\u20132463","journal-title":"Eur Heart J"},{"key":"9689_CR18","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","volume":"37","author":"G Filippatos","year":"2016","unstructured":"Filippatos G, Anker SD, Bohm M, Gheorghiade M, Kober L, Krum H et al (2016) A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease. Eur Heart J 37:2105\u20132114","journal-title":"Eur Heart J"},{"key":"9689_CR19","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1253\/circj.CJ-16-0122","volume":"80","author":"N Sato","year":"2016","unstructured":"Sato N, Ajioka M, Yamada T, Kato M, Myoishi M, Yamada T et al (2016) A randomized controlled study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and\/or Chronic Kidney Disease Circulation Journal. Official J Japanese Circulation Soc 80:1113\u20131122","journal-title":"Official J Japanese Circulation Soc"},{"key":"9689_CR20","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1136\/hrt.2006.107706","volume":"93","author":"MJ Brown","year":"2007","unstructured":"Brown MJ (2007) Renin: friend or foe? Heart 93:1026\u20131033","journal-title":"Heart"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10741-018-9689-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-018-9689-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-018-9689-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T13:19:03Z","timestamp":1570886343000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10741-018-9689-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,12]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["9689"],"URL":"https:\/\/doi.org\/10.1007\/s10741-018-9689-9","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,12]]},"assertion":[{"value":"12 March 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest regarding the overview and meta-analyses, but C.Th. declares consultancy fees from Astra Zeneca, and lecture honoraria from Sanofi, MSD, and Servier.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}